Poor QOL Doesn't Predict Low Survival in High-Risk Lung Cancer Surgery

In surgical publications, Quality Of Life (QOL) is rarely reported. Yet it can be an important metric that can be of use to physicians and patients when making treatment decisions.

Prior studies of average-risk patients undergoing lobectomy suggested that low baseline QOL scores predict worse survival in patients undergoing non-small cell lung cancer surgery. The results of a multi-center, longitudinal study of high-risk lung cancer patients who underwent sublobar resection counters this idea, finding that poor baseline global QOL scores did not predict for worse overall survival or recurrence-free survival or greater risk of adverse events. Bryan F. Meyers, MD, is presenting the results of this research on behalf of the Alliance for Clinical Trials in Oncology at the 94th AATS Annual Meeting in Toronto, ON, Canada on April 29, 2014.

Non-Uniform Genetic Mutations in Lung Cancers may Lead to Targeted Treatment
New research explored tumour heterogeneity – where different cells have different appearances or their own DNA signatures within the same cancer.

"The longitudinal quality of life information now available from this study can be factored into clinical decision-making for high-risk lung cancer patients facing surgery," comments lead investigator Hiran C. Fernando, MD, Chief of the Division of Thoracic Surgery, Boston Medical Center. The results of this study suggest that having poor global quality of life initially should not exclude patients as surgical candidates based on unfounded expectations of poor survival.

The results were generated as part of the Alliance Study (ACOSOG Z4032), in which high-risk operable patients with biopsy proven stage I lung cancers of 3 cm or less were randomized to sublobar resection or sublobar resection with brachytherapy. Two hundred and twelve patients were eligible for the study. Global QOL using the SF-36 (physical [PCS] and mental [MCS] components) were measured at baseline, 3, 12, and 24 months after surgery, as was difficult or labored breathing (dyspnea) using the University of California San Diego (UCSD) scale. The median length of follow-up on alive patients was more than 4 years. Because no differences were found between surgical groups for PCS, MCS, or UCSD measures at any time point, the two surgical groups were combined for data analysis.

In these lung cancer patients, who were generally 70 years of age or older and had poor initial lung function, baseline PCS and MCS scores (that were lower than the U.S. normal values) did not predict poor survival. What did impact overall survival was having breathing problems as measured by low UCSD scores at baseline or experiencing a significant decline in breathing function at 12 months.

Protein Could Improve Small Cell Lung Cancer Therapies: Study
Nearly fifteen percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy.

The study also found that global QOL and dyspnea did not deteriorate significantly after sublobar resection. Those who experienced a significant decline in PCS, MCS, or UCSD at 3 months showed no difference in recurrence-free survival compared to those who showed no such changes.

There were some indications that the surgical technique affected QOL, with better results associated with video-assisted thoracic surgery rather than thoracotomy, and wedge resection rather than segmentectomy.

British Researchers to Take Up Rare Trial for Lung Cancer
To fight advanced lung cancer, British researchers will partner with AstraZeneca and Pfizer to test around 14 drugs simultaneously within one trial.

Source-Eurekalert

Researchers Discover Lactate Metabolism Target That Halts Growth in Lung Cancer Model
Previous research has revealed that cancer cells generate energy differently than normal cells, a characteristic that helps them to survive and spread.